1. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents;O'Connor;Cancer Res,1997
2. p53, and tumor cell sensitivity to anticancer agents;Brown;Cancer Res,1999
3. Influence of TP53 gene alterations and c-erB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer;Geisler;Cancer Res,2001
4. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients;Kandioler-Eckersberger;Clin Cancer Res,2000
5. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer;Chan;J Clin Oncol,1999